Celltrion’s biosimilar Remsima gets EU green light
Published: 2013-07-02 07:00:00
Updated: 2013-07-02 07:00:00
Biopharmaceutical company Celltrion said Monday its biosimilar monoclonal antibody Remsima has won approval by the European Medicines Agency, setting out a clearer path for the local drugmaker to export the drug to 30 countries in Europe.
Remsima is a biosimilar version of U.S. Merck’s Remicad...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
